Congestive heart failure (CHF) is characterised by activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS). Both systems are known to interact and to potentiate each other's activities. We recently demonstrated that angiotensin II (Ang II) enhances sympathetic nerve traffic via prejunctionally-located AT 1 -receptors. At present, little is known about the effects of Ang II at the level of the sympathetic neurones in CHF.
Introduction
Virtually all forms of congestive heart failure (CHF) are known to be accompanied by the activation of neuroendocrine systems, such as the sympathetic nervous system (SNS) and the reninangiotensin-aldosterone system (RAAS). Moreover, peptidergic systems, such as the natriuretic peptides, endothelin and vasopressin, appear to be activated as well. 1, 2 These neurohumoral systems play pivotal roles in the origin and progression of CHF. Additionally, a complex interaction between the SNS and RAAS can be observed in heart failure (HF), characterised by their mutual potentiation. Initially, these responses may contribute to maintain cardiovascular homeostasis and adequate tissue perfusion and they are considered to be adaptive mechanisms in the short term. In the long term, however, activation of these systems, predominantly the RAAS and SNS, causes detrimental effects on cardiac function. It has become clear that increased plasma noradrenaline levels are directly related to prognosis and mortality in CHF. 1, 3, 4 Reduction of plasma noradrenaline level therefore appears to be beneficial, as evidenced by a decrease in CHF mortality with β-blocker treatment. 5 Additionally, attenuating the activity of the RAAS by angiotensin-converting enzyme (ACE)-inhibition or selective AT 1 -receptor blockade is beneficial and well documented. 6, 7 It has become evident that the RAAS enhances the SNS at several sites, including the central nervous system, adrenal medulla, sympathetic ganglia and post-ganglionic nerve terminals. 8 At the level of the sympathetic varicosity,angiotensin II (Ang II) influences sympathetic transmission by blocking noradrenaline uptake, enhancing noradrenaline synthesis and, most importantly, facilitating noradrenaline release. 9 On the other hand, the SNS has been shown to interfere with the RAAS. Stimulation of β-receptors, located in the renal juxtaglomerular apparatus, is known to increase plasma renin levels. Accordingly, it is likely that this mutual potentiation is actively involved in the progression of CHF.The Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS), designed to evaluate neuroendocrine activation and to relate it to prognosis, supports this concept. 10 Chronic ACE-inhibition with enalapril resulted in reduced plasma noradrenaline levels. Additionally, AT 1 -receptor blockade with losartan significantly reduced plasma noradrenaline levels in patients with CHF. 11, 12 The enhanced sympathetic nerve traffic in CHF has been ascribed mainly to an excitatory effect of increased plasma Ang II levels at several sites. However, it has been hypothesised that the ability of the baroreceptor system to control sympathetic nerve traffic is markedly impaired in CHF. 13 Therefore, enhanced sympathetic activity may have a baroreflex origin. RAAS-inhibition has shown to improve both the control of the baroreflex system and the sympathetic nerve traffic in CHF. 13, 14 At the peripheral level (varicosity), Ang II has been shown to enhance sympathetic neurotransmission. The stimulation-induced sympathetic outflow could be facilitated by Ang II via AT 1receptors located at the prejunctional sympathetic membrane. 15 Selective AT 1 -receptor blockade by eprosartan has repeatedly been shown to attenuate Ang II-enhanced sympathetic nerve traffic. 16, 17 At present, the effects of Ang II at the level of the peripheral nervous system have not been fully elucidated in CHF. Therefore, the aim of the present investigation was to study the influence of Ang II on sympathetic nerve traffic (prejunctional AT 1receptor) in an experimental model of HF, induced by pressure-and volume-overload. Additionally, we studied the effect of Ang II on the vasculature (postjunctional AT 1 -receptor). Recently, we addressed this issue by means of functional experiments. 18 However, to properly assess and quantify the SNSactivity, measurement of exocytotic transmitter release offers the most straightforward approach. Accordingly, to study Ang II at the neuronal AT 1receptor, we investigated its influence on electrical field stimulation (EFS)-evoked sympathetic neurotransmission in the isolated rabbit thoracic aorta in a noradrenaline spillover model.To study Ang II effects at the level of the vasculature, concentration-response curves (CRCs) for Ang II were constructed. Furthermore, we investigated the inhibitory effect of the selective AT 1 -receptor antagonist, eprosartan, on Ang II-mediated responses at both pre-and post-synaptic sites.
Methods and animals
Male New Zealand White rabbits were used (nine months old, for body weights (BW) see Table 1 ; n=18 HF group, n=17 control group). The guidelines were followed as presented in 'The Guide for the Care and Use of Laboratory Animals' pub-lished by the US National Institutes of Health.The Committee on Animal Experiments of the Medical Center,Amsterdam, approved the protocol.
Procedure to induce heart failure
The experiment was performed in an animal model, in which HF was induced as described by Bril et al. 19 Accordingly, HF was provoked in two stages. In the first operation, the animals were subjected to general anaesthesia with ketamine, 40 mg/kg BW, and xylazine, 5 mg/kg.Volume-overload was induced by provoking aortic valve insufficiency, by destroying the aortic valve by moving a fluid-filled catheter across the valve. Insufficiency of the aortic valve was characterised by an increase of >50% in pulse pressure. In the second operation, three weeks later, pressure-overload was induced by aortic banding. Via an abdominal incision, a ligature was placed around the aorta, just proximal to the renal arteries, resulting in a reduction of 50% of the aortic diameter. Additional to the anaesthesia described above, inhalation-anaesthesia with isoflurane 0.8% was applied. Animals were ventilated with a mixture of 50% oxygen and 50% air, 2.5 l/minute, 30 strokes/minute.
Assessment of heart failure
Approximately three months after the final procedure, at the age of nine months, the rabbits were anaesthetised with ketamine, 40 mg/kg, and xylazine, 5 mg/kg BW, the left carotid artery was cannulated with a 3F-microtip pressure transducer (Miller, Houston, Texas, USA) and passed into the left ventricle to measure left ventricular end-diastolic pressure (LVEDP). A bolus of 5,000 IU of heparin was injected intravenously (i.v.). Subsequently, the rabbits were sacrificed with pentobarbital, 60 mg/kg i.v. The thorax was opened, and the heart and lungs were excised and weighed.The abdomen was opened to assess the presence of ascites.
Earlier studies using the same model of CHF have demonstrated that there is no difference between the aforementioned parameters of the SHAM-operated rabbits and of those that were not 221 PAPER operated. 19 Therefore, in the present study, we used a control group of rabbits which were age-matched and that had not been subjected to surgery.
Rabbit thoracic aorta preparations
The thoracic aorta was removed and placed in physiological salt solution (PSS) and gassed with a mixture of 95% O 2 and 5% CO 2 at room temperature. Segments of thoracic aorta with a length of 4 mm each were dissected and transferred into an organ bath set-up.The medium was composed as follows (mM): NaCl 118, Na 2 HPO 4 1.2, NaHCO 3 25, KCl 4.7, CaCl 2 1.6, MgSO 4 1.2, and glucose 11.0. Ascorbic acid (0.3 mm) and Na 2 EDTA (0.03 mm) were added to prevent oxidation of noradrenaline.
Three different experiments were performed.
Experiment 1. Electrical field stimulation, angiotensin II and eprosartan
These experiments were performed in a noradrenaline spillover model, thus allowing the selective measurement of sympathetic outflow using tritium-labelled noradrenaline. 20
Radiolabelling of noradrenergic transmitter stores
In order to label their noradrenergic transmitter stores, the aortic rings were incubated for 45 minutes in 2.0 ml of PSS containing 0,1 µmol/l l-[7,8 -3 H]noradrenaline (specific activity 28.8 to 36.0 Ci/mmol) in a 5 ml glass-jacketed organ bath. The medium was continuously bubbled with carbogen and maintained at a temperature of 37°C. After the incubation period, the isolated aortic rings were washed with [ 3 H]noradrenaline-free PSS (10 x 2 ml and 4 x 5 ml) to remove superficially bound, non-neuronal radioactivity before the experimental procedures were started, and mounted vertically between platinum wire electrodes (2 cm) placed along either side of the preparations in a 25 ml organ bath and subjected to a tension of 0.5 g. The organ bath contained 20.0 ml PSS. Desipramine (0.6 µmol/l) and corticosterone (40 µmol/l) were added to rule out uptake-1 and uptake-2 of [ 3 H]noradrenaline, respectively. Yohimbine (1 µmol/l) was added to rule out any α 2 -adrenergic auto-inhibitory effects on [ 3 H]noradrenaline release. The aortic rings were equilibrated for a total period of 48 minutes. After an initial period of 18 minutes, the preparations were subjected to a 2-minute period of EFS with a train of 3 ms rectangular bipolar wave pulses of 150 mA, at a frequency of 2 Hz. (S 0 ) (Danish Myo Technology Current Stimulator, model CS 200). This 'priming' stimulation has proven to increase the reliability and stability of the subsequent basal and EFS-induced [ 3 H]noradrenaline spillover.
Stimulation of intrinsic sympathetic nerves
After the equilibration period, the aortic preparations were subjected to two periods of EFS (see above). The first period of stimulation (S 1 ) was applied directly after the equilibration period of 48 minutes and the radioactivity thus evoked was taken as control value. Subsequently, a second period (S 2 ) was applied 24 minutes after S 1 .
Measurement of tritium-label
Samples of 0.5 ml were repeatedly taken from the organ bath starting 36 minutes after washout. Since the organ bath medium was not changed and its total volume was decreased stepwise by repeated drawing of samples, the actual outflow of radioactivity could be obtained by calculating the incremental accumulation in each sample corrected for the reduced volume.
The mean basal efflux of radioactivity/minutes preceding S 1 and S 2 was determined as the mean outflow/minutes of radioactivity in two 6-minute samples prior to each period of stimulation. The release/minute evoked by EFS (S 1 and S 2 , 2-minute samples) was calculated by subtracting the corresponding mean basal efflux/minute from the apparent evoked efflux/minute. At the end of the experiment, the residual radioactivity of the tissue was measured. By adding the total released radioactivity, the initial content of tritium-label was calculated. The effect of EFS on the release could then be expressed as a fraction of the total tissue content present at the time at which the stimulation period was applied or 'fractional release' of radioactivity (FR 1 and FR 2 ).Accordingly, the effects of pharmacological interventions are expressed as the ratio FR 2 /FR 1 .
Detection of tritium-label in the samples and tissue
After the experiment, the tissues were kept overnight in 2 ml Soluene. Radioactivity was measured by liquid scintillation counting (Tri Carb 2900TR, Packard) in 20-ml aliquots (with either samples or tissue) after addition of 5 ml of scintillation mixture (Ultima Gold). Corrections for counting efficiency were made by external automatic standardisation.
To investigate the influence of Ang II (0.1 nM-0.1 mM) on EFS-evoked noradrenaline release, Ang II was added in one particular concentration to the medium 150 seconds prior to S 2 .To indicate the effect of Ang II, the ratio FR 2 /FR 1 was used.
In another series of preparations, the influence of multiple concentrations of eprosartan (0.1-10 nM) on the interaction between Ang II (10 nM) and stimulation-induced sympathetic outflow was investigated. Either vehicle or eprosartan was added in one particular concentration to the medium 20 minutes before S 2 .Ang II (10 nM) was added 150 seconds prior to S 2 .To characterise the sympatho-inhibitory effects of eprosartan, the ratio FR 2 /FR 1 was used.
Experiment 2. Concentration-response curves of Ang II and eprosartan
The aortic rings were mounted between two triangular stainless steel hooks and placed into an organ bath setup with isometric tension recording. The medium, consisting of 5 ml PSS, was continuously bubbled with carbogen and maintained Isometric tension was measured by means of isometric force transducers (A.D. instruments, Castle Hill, Australia), connected to a MacLab/8 computer system.The aortic rings were equilibrated in PSS for 30 minutes at a resting tension of 20 mN, which was maintained throughout the experiment.The equilibration period was followed by a priming procedure that consisted of a single application of KPSS for 3 minutes (PSS containing 60 mM KCL; equimolar substitution for NaCl), a single concentration of Ang II (0.1 µM), followed by two subsequent KPSS-induced depolarisations. Each stimulus was applied 15 minutes after the preparations had been washed-out repeatedly and had returned to a resting tension of 20 mN.
CRCs to Ang II (1 nM-1 µM) were obtained by single additions with half-log increments 35 minutes subsequent to the priming procedure. In order to investigate the influence of eprosartan on Ang II-elicited contractions, a CRC was constructed for Ang II in the presence of one particular concentration of eprosartan, or vehicle.The antagonist was added to the medium 20 minutes before the administration of Ang II.
Non-linear regression was carried out to calculate the maximal effect (E max ) and the concentration of Ang II that caused half-maximal effects (EC 50 ).The effects of the different concentrations of eprosartan were expressed as percentage of the maximum contractile force elicited by Ang II alone (% E max ).
Experiment 3. Concentration-response curves of noradrenaline and angiotensin II
In addition, CRC of noradrenaline (1 nM-0.1 mM), in the presence of Ang II (1 nM, sub-pressor concentration, added 2 minutes before the CRC was started) or the vehicle, were obtained by single additions with half-log increments 35 minutes subsequent to the priming procedure. The results were calculated and expressed as percentage of the maximum contractile force elicited by the third K + 60 mM depolarisation.
Drugs
Desipramine HCl, yohimbine HCl and N ω -nitro-Larginine (Sigma, USA) were dissolved in distilled water. Corticosterone (Bufa,The Netherlands) was dissolved in dimethylsulphoxide (DMSO). Stock solutions of desipramine (0.6 mM), yohimbine (1 mM) and corticosterone (40 mM) were further diluted with PSS.
Ang II (Bachem, Bubendorf, Switzerland, synthetic human sequence) was dissolved in distilled water. Stock solutions of Ang II (0.1 mM) were stored in 50-µl aliquots at -20ºC.Tritiated levo- [7,8 -3 H]noradrenaline (Amersham Pharmacia Biotech, Little Chalfont, England) had a specific radioactivity of 32.0-36.0 Ci/mmol and a radioactive concentration of 1.0 mCi/ml. Soluene and Ultima Gold solutions were obtained from Packard (Groningen,The Netherlands). Eprosartan (Solvay, Hannover, Germany) was dissolved in NaOH 1M. Using HCl 1M, the pH of the solution was adjusted to 7.5. (-)-Noradrenaline bitartrate (Sigma, USA) was dissolved in distilled water containing L(+) ascorbic acid 1 mg/ml.
Statistical analysis
All data are expressed as means+SEM. Student's ttest (two-tailed, unpaired) was used to evaluate statistical significance of differences between means of control and treatment groups.An ANOVA followed by Dunnett's Multiple Comparison test was used for multiple comparisons with a control group. Differences at p<0.05 were considered to indicate statistical significance. In order to compare the sympatho-inhibitory potency (IC 50 values; the concentration of eprosartan that causes 50% reduction in the enhancement of stimulationinduced radioactivity overflow by Ang II) of eprosartan the fraction of inhibition was determined by subtracting the individual response from the average response seen in the presence of Ang II alone and by dividing that value by the average net increase effected by Ang II relative to the average control response (see equation). Differences at p<0.05 between the IC 50 values were considered to indicate statistical significance.
Results

Basal parameters of the donor animals
The mean BW, relative heart weight (HW) and lung weight (LW), the presence of ascites and the LVEDP concerning the control and HF group are summarised in Table 1 . HW and LW (both related to BW), the incidence of ascites and LVEDP, were significantly increased in HF rabbits.
Experiments 1. Electrical field stimulation, angiotensin II and eprosartan; thoracic aorta
In control experiments, we observed no change in the basal efflux of tritium-label between the different periods of stimulation. Stimulation of the aortic rings resulted in a marked increase of tritium spillover by a factor of approximately six in both groups (p<0.05 compared with basal outflow, p>0.05 between control and CHF-preparations). Additionally, no difference between groups was observed regarding the absolute tritium-label released (data not shown).
Furthermore, in both groups the fractional release of EFS-evoked tritium-label remained constant throughout the experiment (control; FR 2 /FR 1 0.99+0.04, n=8, CHF; 1.01+0.05, n=6).To validate that the evoked tritium-label spillover was of neuronal origin, we determined the influence of tetrodotoxin (1 µM) on EFS-evoked sympathetic outflow. Tetrodotoxin nearly abolished the EFSevoked tritium release (data not shown), thus indicating that noradrenaline was indeed released from In both CHF-and control preparations, Ang II added to the organ bath in one particular concentration 150 seconds before S 2 , did not alter the efflux at rest. However, it caused a concentrationdependent increase of the stimulation-evoked sympathetic outflow (maximum produced by 10 nM Ang II; control FR 2 /FR 1 2.03+0.11 [n=7] and CHF FR 2 /FR 1 1.71+0.07 [n=7]) ( Figure 1 ). The maximal enhancement differed significantly between the groups (p<0.05 CHF-preparations compared with control).
Addition of eprosartan to the medium 20 minutes before S 2 neither influenced the resting efflux of tritium-label nor the noradrenaline spillover evoked by EFS (data not shown). However, eprosartan concentration-dependently attenuated the subsequent Ang II-enhanced (10 nM) sympathetic outflow (Figures 2A and 2B) .
We compared the sympatho-inhibitory potency of eprosartan between the control and CHF-preparations ( Figure 3) . We calculated the percentage of inhibition by each concentration of eprosartan in both groups as indicated in the Methods section. Linear regression calculations adequately described the relationship between inhibition (in terms of percentage) and the different concentrations of eprosartan.We observed no difference between the inhibitory potency of eprosartan in control and CHF-preparations (control pIC 50 8.81+0.31; CHF pIC 50 8.65+0.42, p<0.05).
Experiment 2. Concentration-response curves of angiotensin II and eprosartan
Ang II (1 nM-0.3 µM) caused a concentrationdependent increase in contractile force in control preparations (E max 21.64+3.86 mN, pD 2 7.63+0.02, n=7). Eprosartan (1 nM-0.1 µM) influenced the Ang II-contractions in a mixed form of antagonism ( Figure 4 ). Interestingly, Ang II (0.1 µM) caused a very small, non-significant contraction in the HF group.In addition,the third potassium-induced contraction in CHF-preparations was significantly decreased compared to that in control preparations (13.02+0.64 mN versus 30.40+0.89 mN, Figure 5A ). In order to determine whether the Ang II-mediated contractions, (0.1 µM) in both groups were the same when compared to the potassium-induced contractions, we calculated and plotted them as percentage of the third potassium-induced contractions ( Figure 5B ).
Experiment 3. Concentration-response curves of noradrenaline and angiotensin II
CRCs to noradrenaline (% of potassium chloride) were very similar in control and CHF-preparations, respectively. Noradrenaline caused a concentrationdependent increase in contractile force of aortic rings in both groups ( Table 2 ). p>0.05 for both E max and EC 50 -values.
Vasoconstrictor responses to noradrenaline remained unchanged by the presence of Ang II (Table 2 ). p>0.05 compared with control for both E max and EC 50 -values.
Discussion
The present study indicates that in vessels from CHFrabbits the neuronal response to Ang II is decreased compared with responses observed in vessels from control rabbits.These findings may be explained by down-regulation or uncoupling of the AT 1 -receptor at the sympathetic varicosity. Additionally, the basal contractility of the thoracic aorta was negatively influenced, probably due to neurohumoral and/or functional changes associated with HF. Application of volume-and pressure-overload in the donor animals resulted in a significant increase in HW, LW, LVEDP and incidence of ascites (see Table 1 ). These changes mimic the progressive alterations observed in HF, as observed in a previous study using the same HF-model. 21 In that study, a combination of a HW/BW ratio (g/kg) of >4.6, a LW/BW ratio of >3.5 (g/kg) and a LVEDP >5 mmHg was assumed to indicate HF. Consequently, in the present study, volume-and pressure-overload led to a significant degree of HF.
The EFS-evoked release of radioactivity from control and CHF-preparations was similar. Therefore, the integrity of the sympathetic nerve terminals in HF-preparations appears not to be affected concerning noradrenaline uptake activity, and neuronal catecholamine content, as well as contents of tyrosine hydroxylase and neuropeptide Y, as was reported in the myocardium of rabbits with pacing-induced HF. 22 Responses to EFS were reported to be similar in control and HFpreparations previously, in both humans and animal models. 18, 23 Ang II concentration-dependently enhanced the stimulation-evoked noradrenaline release in control and CHF-preparations. Interestingly, in CHF-preparations the maximal augmentation mediated by Ang II was reduced compared with the enhancement observed in controls, although the potency of Ang II remained unchanged. Furthermore, in control and CHF-preparations the facilitation by Ang II could be inhibited by the selective AT 1 -antagonist, eprosartan. Accordingly, augmentation of sympathetic nerve traffic in CHFrabbits, as well as in control animals, appears to be mediated by the prejunctional AT 1 -receptor, as was demonstrated by us and others in non-pathological models. 15, 24, 25 The facilitating effect of Ang II being less in CHF-compared with control preparations may be explained by down-regulation or desensitisation/uncoupling of the AT 1 -receptor, which has been described previously. 18, [26] [27] [28] In general, increased levels of Ang II are assumed to be the main cause of down-regulation. 26, 29 Although, in the present study, stimulationinduced release of tritium-label was not different in controls compared with CHF-preparations, changes in function of the sympathetic nerve terminal, as well as changes in the signalling pathway, may possibly play a role in the decreased facilitation by Ang II in CHF-preparations. The inhibitory potency of eprosartan did not differ between control and CHF-preparations, as previously shown. 18 Therefore, despite the reduced facilitating effect of Ang II in HF, the affinity of eprosartan for the prejunctional AT 1 -receptor remained unchanged.
At the level of the vasculature, the response to potassium decreased to approximately 60% compared with the response in control preparations. The responses to noradrenaline (% of contractility to potassium chloride) were similar in control and CHF-preparations. Therefore, it appears that a receptor-independent mechanism is responsible for decreased noradrenaline and potassiuminduced contractility in the CHF-preparations. Functional studies addressing the vascular responsiveness to many vasoactive substances in HF have yielded conflicting outcomes. [30] [31] [32] [33] Factors involved may be receptor desensitisation and endothelial integrity/function, in addition to vascular structure adaptations. The decreased aortic contractility probably involves structural changes, such as remodelling and collagen accumulation, secondary to either increased pressure or neurohumoral changes associated with HF (highly activated RAS and SNS), as was previously suggested. 34, 35 The response to Ang II was nearly abolished in HF preparations. Decreased responses to Ang II in the rabbit aorta suffering from HF were demon-strated previously, and were ascribed to desensitisation of Ang II receptors secondary to an activated RAS. 36 It may therefore be possible that desensitisation of the AT 1 -receptor, in addition to structural changes of the vasculature, are responsible for the decreased response to Ang II in the present study.
We previously demonstrated that in the mesenteric artery of the same CHF-model the postjunctional receptor-dependent (noradrenaline) and independent (potassium) responses were similar to responses in control preparations. 18 In the present study, however, they were impaired in the thoracic aorta. It has been demonstrated that at the level of the mesentery and other small arteries, CHF does not affect vascular structure 37 and therefore the responses may be unchanged. Additionally, no depression of Ang II-mediated responses (% of contractility to potassium) was observed in the mesenteric artery, which we suggested to be a result of receptor reserve. A tissue-dependent difference in receptor reserve might therefore possibly explain the difference in Ang II responses between the mesenteric artery and the thoracic aorta of the CHF rabbit, although this has to be substantiated.
Eprosartan displayed a mixed type of antagonism in control preparations, combining a rightward shift of the concentration-effect curve and a suppression of E max . In a previous study, using the rabbit thoracic aorta preparation, we observed a type of antagonism that is consistent with competitive antagonism, 16 as was reported previously. 38, 39 The present phenomenon is complex, precluding any clear interpretation about changes in receptor function, expression or coupling. However, it was demonstrated that differences in the type of antagonism displayed by the nonpeptide AT 1 -receptor antagonist, BIBS 222, might be explained by a desensitisation/down-regulation of the AT 1 -receptor. 40 It can be imagined that age, the sole factor being different in the present compared to our previous study, might influence the AT 1 -receptor expression and consequently the antagonistic profile of eprosartan.
Ang II (1 nM, which proved to significantly enhance stimulation-evoked sympathetic nerve traffic) did not alter the responses to noradrenaline, excluding an interaction with the α-adrenoceptor at the level of vascular smooth muscle cell, as evidenced by some authors. 41, 42 In the rabbit ear artery, as in the present study, no effect of Ang II on noradrenaline responses was observed. 43 In conclusion, Ang II-enhanced sympathetic traffic is mediated by the prejunctional AT 1 -receptor Nap 
